Pekin Hardy Strauss Inc. Invests $541,000 in ClearPoint Neuro, Inc. (NASDAQ:CLPT)

Pekin Hardy Strauss Inc. purchased a new position in shares of ClearPoint Neuro, Inc. (NASDAQ:CLPT - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 48,250 shares of the company's stock, valued at approximately $541,000. Pekin Hardy Strauss Inc. owned about 0.17% of ClearPoint Neuro as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently bought and sold shares of CLPT. Rinkey Investments purchased a new position in shares of ClearPoint Neuro in the 2nd quarter worth about $307,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in ClearPoint Neuro in the second quarter valued at approximately $175,000. Price T Rowe Associates Inc. MD lifted its position in ClearPoint Neuro by 7.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 24,867 shares of the company's stock valued at $170,000 after buying an additional 1,813 shares in the last quarter. Squarepoint Ops LLC acquired a new position in ClearPoint Neuro during the second quarter valued at approximately $549,000. Finally, Renaissance Technologies LLC grew its stake in ClearPoint Neuro by 562.6% during the second quarter. Renaissance Technologies LLC now owns 169,700 shares of the company's stock worth $915,000 after buying an additional 144,088 shares during the period. Hedge funds and other institutional investors own 30.08% of the company's stock.

Wall Street Analyst Weigh In

Separately, Lake Street Capital upped their price target on shares of ClearPoint Neuro from $11.00 to $15.00 and gave the stock a "buy" rating in a research report on Tuesday, August 27th.

ClearPoint Neuro Price Performance

ClearPoint Neuro stock traded down $0.17 during midday trading on Monday, hitting $11.67. 184,654 shares of the company were exchanged, compared to its average volume of 189,099. The company has a market cap of $321.86 million, a PE ratio of -16.91 and a beta of 1.10. ClearPoint Neuro, Inc. has a fifty-two week low of $5.11 and a fifty-two week high of $14.13. The company's fifty day moving average price is $11.89 and its 200-day moving average price is $9.27.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.